

Epilepsy and Ovarian Hormones

Editorial Board

Cynthia L. Harden, MD (Series Editor)

Associate Professor of Neurology and Neuroscience
Comprehensive Epilepsy Center
Weill Medical College of Cornell University
New York, New York

Gus A. Baker, PhD, FBPSS

Professor of Clinical Neuropsychology
Department of Neurological Science
Clinical Science Centre for Research and Education
University of Liverpool
United Kingdom

Cheryl A. Frye, PhD

Associate Professor of Neuroscience
Departments of Psychology, Biology,
and Center for Neuroscience Research
University at Albany
State University of New York
Albany, New York

Georgia D. Montouris, MD

Assistant Professor of Neurology
Department of Neurology
Associate Director of Epilepsy Services
Boston University School of Medicine
Boston, Massachusetts

Page B. Pennell, MD

Associate Professor of Neurology
Director, Emory Epilepsy Program
Emory University School of Medicine
Atlanta, Georgia

Mary L. Zupanc, MD

Professor, Department of Pediatrics and Neurology
Chief, Division of Pediatric Neurology
Director, Pediatric Comprehensive Epilepsy Program
Medical College of Wisconsin
Children's Hospital of Wisconsin
Milwaukee, Wisconsin

Disclosure

It is the policy of Emory University School of Medicine to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. All faculty participating in our programs are expected to disclose any relationships that they may have with commercial companies whose products or services may be mentioned so that participants may evaluate the objectivity of the information presented. In addition, any discussion of off-label, experimental, or investigational use of drugs or devices will be disclosed. The faculty reported the following:

Dr Harden reports that she has been a speaker and a member of the advisory board for UCB Pharma, Inc, sponsor of this activity.

Dr Baker reports no financial interest in or other relationship with any health care company.

Dr Frye reports no financial interest in or other relationship with any health care company.

Dr Montouris has no financial interest in any health care company and reports the following types of relationships with health care companies: *Speakers' Bureau*, with Abbott Laboratories; Eisai; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer Inc; Ortho-McNeil

Pharmaceutical, Inc; Cyberonics, Inc; UCB Pharma, Inc; *Research*, with Schwarz Pharma; UCB Pharma, Inc; GlaxoSmithKline; *Advisory Board (Consultant)*, with Abbott Laboratories; Eisai; Novartis Pharmaceuticals Corporation.

Dr Pennell received compensation for consulting on an advisory board and speaking honoraria from GlaxoSmithKline and UCB Pharma, Inc. She received compensation for consulting professional readings from SleepMed DigiTrace and financial support for research from GlaxoSmithKline and Pfizer Inc. Dr Pennell also received financial support for educational activities from Ortho-McNeil Pharmaceutical, Inc.

Dr Zupanc has served as consultant and on speaker boards for Ortho-McNeil Pharmaceutical, Inc; GlaxoSmithKline; and Novartis Pharmaceuticals Corporation. She has also served as a consultant for UCB Pharma, Inc; Xcel Pharmaceuticals; and MedPointe Pharmaceuticals.

Intended Audience

Neurologists who treat women with epilepsy

Learning Objectives

At the conclusion of this activity, participants should be able to

- Describe the effects of ovarian hormones on epileptogenesis, including the seizure threshold, and the association of seizure patterns with the menstrual cycle
- Identify potential drug to drug interactions between antiepileptic drugs and other medications
- Discuss the incidence and pathogenesis of higher rates of infertility, reproductive endocrine disorders, and overall sexual dysfunction in women with epilepsy
- Discuss the evidence for teratogenicity and cognitive dysfunction in the offspring of women with epilepsy receiving pharmacotherapy

Continuing Medical Education Credit

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Emory University School of Medicine and The BioContinuum Group. Emory University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Emory University School of Medicine designates this educational activity for a maximum of 2.5 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

Release date: May 2005

End date: May 31, 2008

Disclaimer

The content and views presented in this educational activity are those of the editorial board and do not necessarily reflect those of the sponsors. Disclosure of commercial relationships, if any, and discussions of unlabeled or unapproved uses of drugs or medical devices will be made. Before prescribing any medication, primary references and full prescribing information should be consulted.

Jointly sponsored by Emory University School of Medicine and The BioContinuum Group



Acknowledgment



Support for this activity has been made possible through an educational grant from UCB Pharma, Inc.